Atypical antipsychotics: matching receptor profile to individual patient's clinical profile

CNS Spectrums
Darius K Shayegan, Stephen M Stahl

Abstract

Understanding common pharmacologic and clinical "class" actions associated with atypical antipsychotics certainly reveals how these agents are alike, but what about unique differences from one agent to another? Atypical antipsychotics are also a heterogeneous group of agents that have complex pharmacologic entities, acting upon multiple dopamine receptors (D2, D1, D3, and D4) and multiple serotonin receptors (5-HT2A, 5-HT2C, 5-HT1A, and 5-HT1D, among others). Atypical antipsychotics also interact with noradrenergic (alpha 1- and alpha 2-adrenergic receptor blockade), histaminergic (H1-receptor blockade), and cholinergic (muscarinic M1 blockade) neurotransmitter systems as well as with monoamine (D, 5-HT, and norepinephrine reuptake blockade) transporters. However, no two atypical antipsychotics possess the same portfolio of actions upon all of these additional neurotransmitter systems.

References

Mar 9, 2007·International Journal of Clinical Practice·L Citrome
Jul 17, 2007·European Archives of Psychiatry and Clinical Neuroscience·Michael RiedelHans-Jürgen Möller
Feb 22, 2011·Expert Opinion on Drug Safety·L Citrome
Mar 27, 2012·European Child & Adolescent Psychiatry·Eiji Kirino
Mar 1, 2012·Expert Review of Neurotherapeutics·Joshua T Kantrowitz, L Citrome
May 6, 2014·CNS Drugs·Rachel HershenbergOlga Brawman-Mintzer
Dec 18, 2014·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Eiji Kirino
Aug 21, 2015·Expert Review of Neurotherapeutics·Rene S Kahn, Amalia Giannopoulou
Dec 10, 2016·Psychopharmacology·Yury S TarahovskyNadezhda M Zakharova
Jan 13, 2006·CNS Spectrums·Sara Goldman
Jun 21, 2006·Expert Review of Neurotherapeutics·Kimberly H LittrellNicole M Wolf
Aug 10, 2013·The British Journal of Psychiatry : the Journal of Mental Science·T GerhardS Crystal
Nov 1, 2008·Expert Review of Clinical Pharmacology·Meera NarasimhanPrakash Masand
Jun 5, 2014·Pharmacogenomics·Mark D Brennan
Aug 8, 2007·The International Journal of Neuropsychopharmacology·Stephen M Stahl
Feb 28, 2008·International Clinical Psychopharmacology·Stuart A Montgomery
May 6, 2014·Expert Opinion on Drug Metabolism & Toxicology·L Citrome
Nov 25, 2017·Paediatric Drugs·Ekaterina StepanovaRobert L Findling
Apr 8, 2018·Current Medical Research and Opinion·Daisy Ng-MakAntony Loebel
Feb 10, 2007·Current Medical Research and Opinion·Jean-Pierre DoréeS Valérie Tourjman
Feb 7, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·F Bellivier
Oct 4, 2020·BMC Medical Genetics·Xiaoqian FuConghua Zhou

Citations

Dec 1, 1990·The British Journal of Psychiatry : the Journal of Mental Science·D J King
Nov 1, 1989·Journal of Abnormal Psychology·H E Spohn, M E Strauss
Oct 1, 1993·Clinical Neuropharmacology·M Briley, C Moret
Jan 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·R L Jakab, P S Goldman-Rakic
May 18, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C P LawlerRichard Mailman
Jul 22, 1999·Annals of the New York Academy of Sciences·P S Goldman-Rakic
Aug 22, 2001·European Journal of Pharmacology·A W SchmidtS H Zorn
Feb 19, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Junji IchikawaHerbert Y Meltzer
Mar 1, 2002·Journal of Affective Disorders·E VietaH S Akiskal
Sep 13, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefania BonaccorsoJunji Ichikawa
Nov 5, 2002·Schizophrenia Research·Tomiki SumiyoshiHerbert Y Meltzer
Nov 15, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterKenneth W Perry
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wesley K KroezeBryan L Roth
May 29, 2003·Current Drug Targets. CNS and Neurological Disorders·C A Tamminga, A Carlsson
Jun 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David A ShapiroRichard Mailman
Jun 19, 2003·JAMA : the Journal of the American Medical Association·J Douglas BremnerDennis S Charney
Jan 8, 2004·Journal of Clinical Psychopharmacology·Edmund P HarriganMichelle Middle
Apr 2, 2004·The American Journal of Psychiatry·Stephen V FaraoneMing T Tsuang
Jun 23, 2004·Journal of Clinical Psychopharmacology·John M Davis, Nancy Chen
Jun 30, 2004·CNS Drugs·Bruce J KinonPeter F Buckley
Jul 15, 2004·Annals of the New York Academy of Sciences·Hilary P BlumbergBradley S Peterson

Related Concepts

Antipsychotic Effect
HTR1D gene
Seroquel
Schizophrenia
Dibenzothiazepines
HTR2A wt Allele
Piperazines
Serotonin
Receptors, Tryptamine
HTR2A gene

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Related Papers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Niels H JensenBryan L Roth
Przegla̧d lekarski
Krzysztof CiszowskiWojciech Jawień
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Mellar P Davis
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
H Y Meltzer
© 2020 Meta ULC. All rights reserved